New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Go back to New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 3.89 -0.25 (6.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.14 | 52 Week High | $45.34 | |||
| Open | $4.15 | 52 Week Low | $15.92 | |||
| Day High | $4.17 | P/E | 1.67 | |||
| Day Low | $3.86 | EPS | $2.33 | |||
| Volume | 3,509,964 | |||||
